| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2017: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2016: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2015: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
We have reported the following studies regarding severe hypoglycemia and use of beta-blockers in patients with diabetes:
“The incidence of abnormal QT prolongation during severe hypoglycemia may be significantly higher in the early morning (Ann Med. 2015;47:238-44),”“Prior use of beta-blockers may prevent adverse influences during severe hypoglycemia in diabetic patients (Medicine. 2015;94:e1629),” “Intensive glycemic therapy may be effective in patients with type 2 diabetes receiving treatment with β-blockers (Diabetes Care. 2016;39:1818-26),” “In patients with diabetes and coronary heart disease, the use of β-blockers may be effective in reducing all-cause mortality in those with myocardial infarction/heart failure with reserved ejection fraction but not in those without (Diabetes Obes Metab. 2017;19:800-808),” and“The use of β-blockers in patients with diabetes may be associated with an increased risk for cardiovascular events (Hypertension. 2017;70:103-110).”
|
